|Bid||36.050 x 0|
|Ask||36.250 x 0|
|Day's Range||36.000 - 36.600|
|52 Week Range||29.300 - 45.750|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
A look at the shareholders of CanSino Biologics Inc. (HKG:6185) can tell us which group is most powerful. Institutions...
Biotech company Hutchison China MediTech, known as Chi-Med, has filed for a Hong Kong listing, which four sources close to the matter said could raise up to $500 million. Chi-Med, which is already listed on the London Stock Exchange and the Nasdaq in New York, filed its listing application with the Hong Kong stock exchange on Monday. "We are delighted to announce our proposed Hong Kong listing and global offering of shares," said Simon To, Chairman of Chi-Med, which is 60.2 percent owned by CK Hutchison.